GILD vs BIIB — Key Metrics

Metric GILD (GILEAD SCIENCES INC) BIIB (BIOGEN INC)
Price168.98251.41
Market Cap209.59 Billion37.16 Billion
P/E (TTM)-54.51106.53
P/B (Quarterly)16.2351.907
P/S (TTM)6.763.61
Net Profit Margin (TTM)-12.53.4
Gross Margin (TTM)79.974.0
ROE (TTM)-21.71.9
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

GILEAD SCIENCES INC
vs
 
BIOGEN INC
 
GILEAD SCIENCES INC
vs
 
BIOGEN INC
Performance Comparison
AI Model Recommendation
GILD · GILEAD SCIENCES INC

Outperform

57
UnderperformOutperform
BIIB · BIOGEN INC

Greatly Outperform

76
UnderperformOutperform
Recommendation Summary

Stock GILD is projected to outperform the market, stock BIIB is projected to greatly outperform the market. Upfront Recommendation: BIIB.

Financial Metrics
Prices delayed ~15 min
GILD Metrics BIIB
$168.98 Price $251.41
— Market Capitalization —
6.76 Price to Sales 3.61
15.21 Price to FCF Ratio 18.09
8.46 Price to Gross Profit 4.88
33.12 Price to R&D 17.27
12.66 Price to Current Assets 4.9

GILD vs BIIB at a glance

Gilead Sciences INC (GILD) and Biogen INC (BIIB) are both Drug Manufacturers - General companies in the Healthcare sector. GILD is the larger, at $209.6 billion in market value against $37.2 billion for BIIB, about 5.6 times the size.

On trailing-twelve-month figures, GILD trades at 6.8 times trailing sales and BIIB at 3.6; net profit margins are -12.5% and 3.4%.

The Upfront Investment model currently rates GILD Outperform and BIIB Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.